It is coming up on the end of the year and many MT Group customers have reached out to optimize their remaining 2022 biospecimen budgets. We have strong access to diverse FFPE tissues including:
Rare FFPEs
- Cancer patients that were collected after receiving immuno-oncology (IO) therapeutics or traditional chemotherapy regimens
- Lymphoma patients that were collected both before R-CHOP therapy and after / on R-CHOP therapy (matched pre- and post- therapy sets)
- Metastatic bladder cancer patients who had failed one or more systemic therapy regimens before tissue collection
- Castration-resistant prostate cancer patients that then went on to develop metastatic disease
Other FFPEs
- NSCLC, breast, colon, and other primary tumors
- Other non-cancer, diseased tissues
- Non-diseased organs
